New England Drug Metabolism Discussion Group
Career Postings
Suggest a Speaker or Topic
Steering Committee
Email Webmaster


Company: Radikal Therapeutics
Location: Beverly, MA, USA
Job Title:
To Apply: Submit resume to


Radikal Therapeutics is seeking highly motivated scientists to join its Drug Metabolism group in Beverly, MA.

  • Successful candidates will undertake profiling and characterization of metabolites derived from small molecules and natural products in biological matrices.
  • They should be experienced in biotransformation of drugs and structural elucidation by LC-MS.
  • In addition, candidates should be flexible and capable of working independently and as part of a small team, in a dynamic environment, supporting in vitro and vivo preclinical and clinical ADME studies.
Please submit your resume to

Radikal Therapeutics (RTX) is a multi-national biotechnology firm focused on the discovery and development of transformative pharmaceuticals. With a deep pipeline of therapeutics created in-house, and a paradigm-disruptive discovery engine, we are positioned to remain at the forefront of drug discovery.

Our team of chemists, biologists, immunologists, and drug development professionals have worked together for more than two decades and have built a reputation for leadership in basic science and drug development. The company is developing best-in-class therapeutics in a range of clinical areas including inflammation, ischemia-reperfusion injury, auto-immunity, and prematurity.

Our product platforms include small and large molecule pharmaceuticals that therapeutically restore free radical equilibrium, redirect aberrant signaling pathways in inflammation, manipulate mitochondrial cell death pathways, modulate DNA repair, restore microcirculatory perfusion, and induce specific immunotolerance.

Although varied in their structural targets and directed at diverse clinical needs, our technologies share a unified concept of correcting pathophysiology by endowing agents with multi-functional capacity. This approach yields biological synergies that far outstrip the potency of traditional single-target agents.

RTX makes available its deep and unique experience in pharmaceutical development via its contract services firm Luria Scientific Industries (LSI).